drugset / Trial / NCT05693090
Tipifarnib and Osimertinib in EGFR-mutated Non-Small Cell Lung Cancer
Non-randomizedSequentialOpen-labelTreatment
Summary
This is a Phase 1a/b, multicenter, open-label, dose escalation (1a) and dose expansion (1b) study. The purpose of this study is to measure safety, tolerability, and preliminary efficacy with the combination of tipifarnib with osimertinib in patients with advanced/metastatic EGFR-mutated non-small cell lung cancer.
Timeline
- Start
- 2023-02-01
- Primary completion
- 2027-07-27
- Completion
- 2027-07-27
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Osimertinib | Small molecule | — | Oral |
| Subject | tipifarnib | Small molecule | — | Oral |